查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1667965

纤溶酶原市场 - 全球产业规模、份额、趋势、机会和预测，按类型、应用、地区和竞争细分，2020-2030 年预测

Plasminogen Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球纤溶酶原市场价值为 26.5 亿美元，预计到 2030 年将达到 36.4 亿美元，年复合成长率(CAGR) 为 5.43%。随着人们越来越认识到基于纤溶酶原的疗法可以治疗多种疾病，特别是伤口癒合和眼部疾病，市场正在获得相当大的发展势头。纤溶酶原是参与纤维蛋白溶解的关键蛋白质，对于分解血栓和促进伤口癒合至关重要。糖尿病等慢性疾病的发生率不断上升，常常导致糖尿病足溃疡，这推动了对基于纤溶酶原的治疗的需求。此外，生物技术的进步和越来越多的针对纤溶酶原疗法的临床试验增强了人们对其治疗潜力的信心。随着持续的研究强调其应用，预计市场将大幅成长，并为木样结膜炎和慢性伤口等病症提供多样化的治疗选择。

市场概况
预测期 2026-2030
2024 年市场规模 26.5 亿美元
2030 年市场规模 36.4 亿美元
2025-2030 年复合年增长率 5.43%
成长最快的领域 伤口癒合
最大的市场 北美洲

推动纤溶酶原市场快速成长的关键因素包括个人化医疗的兴起和新兴经济体医疗保健基础设施的扩张。随着医疗保健的发展，人们更加重视个人化治疗计划，预计这将增加纤溶酶原疗法的采用。此外，医疗保健领域的投资，尤其是亚太和拉丁美洲等地区的投资，正在推动市场成长。全球范围内外科手术的增加以及随之而来的术后护理需求增加了对纤溶酶原疗法的需求，特别是在伤口护理和组织再生方面。此外，临床试验的良好结果吸引了投资者的兴趣，推动了基于纤溶酶原的产品的持续创新和开发。

然而，纤溶酶原市场面临一些可能阻碍其成长轨迹的挑战。一个主要障碍是製造基于纤溶酶原的疗法的成本高，这可能会限制其可及性，特别是在低收入国家。监管挑战，包括新的纤溶酶原治疗方法的严格审批程序，也为寻求引入创新解决方案的公司带来了障碍。儘管存在这些挑战，但持续的临床进步和对有效伤口癒合解决方案日益增长的需求为主要市场参与者提供了巨大的成长机会。降低治疗成本和简化审批流程的努力有望解决这些挑战并进一步增强市场潜力。

主要市场驱动因素：

血块相关疾病盛行率不断上升

主要市场挑战：

治疗费用高昂

主要市场趋势：

监管支持和临床试验

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第四章：全球纤溶酶原市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依类型（静脉注射、眼药水）
    • 依用途分类（木结膜炎、糖尿病足、伤口癒合、其他）
    • 按公司分类（2024）
  • 市场地图
    • 按类型
    • 按应用
    • 按地区

第 5 章：亚太地区纤溶酶原市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按类型
    • 按应用
    • 按国家
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第六章：欧洲纤溶酶原市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美纤溶酶原市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 墨西哥
    • 加拿大

第 8 章：南美洲纤溶酶原市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲纤溶酶原市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：市场动态

  • 驱动程式
  • 挑战

第 11 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 12 章：全球纤溶酶原市场：SWOT 分析

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Boehringer Ingelheim Inc. GmbH
  • Kedrion SpA
  • Genentech
  • Prometic Life Sciences Inc
  • Grifols, SA
  • Octapharma AG
  • Green Cross Corporation
  • Baxter International Inc.
  • CSL Behring LLC
  • Renaissance Acquisition Holdings LLC

第 15 章：策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 19040

The global plasminogen market was valued at USD 2.65 billion in 2024 and is projected to reach USD 3.64 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.43%. The market is gaining considerable momentum due to the growing recognition of plasminogen-based therapies for treating a variety of medical conditions, particularly in wound healing and ocular diseases. Plasminogen, a crucial protein involved in fibrinolysis, is essential for breaking down blood clots and promoting wound healing. The rising prevalence of chronic diseases, such as diabetes, which often leads to diabetic foot ulcers, is driving the demand for plasminogen-based treatments. Additionally, advancements in biotechnology and the increasing number of clinical trials focusing on plasminogen therapies are bolstering confidence in its therapeutic potential. With ongoing research highlighting its applications, the market is expected to grow significantly, offering diverse treatment options for conditions like ligneous conjunctivitis and chronic wounds.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.65 Billion
Market Size 2030USD 3.64 Billion
CAGR 2025-20305.43%
Fastest Growing SegmentWound Healing
Largest MarketNorth America

Key factors contributing to the rapid growth of the plasminogen market include the rise of personalized medicine and the expansion of healthcare infrastructure in emerging economies. As healthcare evolves, there is a greater focus on individualized treatment plans, which is anticipated to increase the adoption of plasminogen therapies. Additionally, investments in healthcare, especially in regions such as Asia-Pacific and Latin America, are driving market growth. The global rise in surgical procedures and the subsequent need for post-operative care have increased the demand for plasminogen therapies, particularly in wound care and tissue regeneration. Moreover, promising results in clinical trials have attracted investor interest, fueling continued innovation and the development of plasminogen-based products.

However, the plasminogen market faces several challenges that may impede its growth trajectory. One major obstacle is the high cost of manufacturing plasminogen-based therapies, which could limit their accessibility, particularly in low-income countries. Regulatory challenges, including rigorous approval processes for new plasminogen treatments, also present barriers for companies seeking to introduce innovative solutions. Despite these challenges, ongoing clinical advancements and the growing demand for effective wound healing solutions provide substantial growth opportunities for key market players. Efforts to reduce treatment costs and streamline the approval process are expected to address these challenges and further enhance the market's potential.

Key Market Drivers:

Rising Prevalence of Clot-Related Disorders

The increasing prevalence of clot-related disorders is a significant driver of the global plasminogen market. Conditions such as venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) have become more common due to factors such as sedentary lifestyles, rising obesity rates, and an aging population. In India, the incidence of DVT is reported to be 1% among adults over 40, with 15% to 20% of hospitalized patients affected. These disorders, which result from the abnormal formation of blood clots, can lead to serious complications like stroke, heart attacks, and respiratory failure, making timely treatment essential.

Plasminogen plays a key role in preventing or resolving clot-related complications. A deficiency or dysfunction of plasminogen can impede the body's ability to dissolve clots, increasing the risk of thrombotic events. As these disorders become more prevalent, the demand for plasminogen-based therapies to manage these life-threatening conditions is rising. Treatments involving plasminogen help dissolve existing clots and prevent new ones, improving patient outcomes and reducing complications. The growing number of diagnoses, coupled with improved diagnostic techniques and greater awareness, has expanded the patient base seeking effective treatment. This has led pharmaceutical companies to invest significantly in developing innovative plasminogen therapies, including recombinant plasminogen products, to address the growing demand for safe and effective clot management solutions.

Key Market Challenges:

High Treatment Costs

The high treatment costs associated with plasminogen-based therapies present a significant challenge to ensuring equitable access. The complex production of recombinant plasminogen products contributes to their elevated prices. The biotechnology processes involved in synthesizing plasminogen require sophisticated equipment, specialized expertise, and stringent quality control measures. Research, development, and manufacturing costs are substantial, and these expenses are often passed on to patients and healthcare systems.

Additionally, regulatory requirements add to the overall cost. Companies must invest significantly in preclinical and clinical trials to demonstrate the safety and efficacy of plasminogen treatments, meeting the rigorous standards set by regulatory agencies such as the FDA and EMA. These trials involve extensive data collection and monitoring, further contributing to the cost.

The limited patient pool also drives up treatment costs. While clot-related disorders are prevalent, they do not affect as large a population as other medical conditions, preventing the economies of scale that could reduce production costs for plasminogen therapies.

Key Market Trends:

Regulatory Support and Clinical Trials

Regulatory support and clinical trials are crucial drivers for the growth of the global plasminogen market. Regulatory agencies such as the FDA and EMA play an essential role in ensuring the safety and efficacy of plasminogen-based therapies, providing the necessary frameworks for drug approval and market entry. In India, the Central Drugs Standard Control Organization (CDSCO) has expedited the approval of critical therapies, including novel plasminogen replacement treatments for congenital plasminogen deficiency.

Clinical trials form the foundation for the development of plasminogen therapies, providing the evidence needed to validate their safety and effectiveness. As the number of clinical trials increases, so does the confidence in plasminogen's potential, both among healthcare providers and regulatory agencies. In 2024, the Clinical Trials Registry - India (CTRI) reported a 15% increase in registered clinical trials for plasminogen therapies. Notably, a Phase III trial aimed at evaluating recombinant plasminogen for chronic venous leg ulcers is underway, further demonstrating the commitment to advancing plasminogen-based therapies.

The support from regulatory bodies like the FDA, EMA, and CDSCO is instrumental in expediting the approval process and ensuring the continued development and accessibility of plasminogen therapies, ultimately improving patient outcomes.

Key Market Players:

  • Boehringer Ingelheim Inc. GmbH
  • Kedrion S.p.A
  • Genentech
  • Prometic Life Sciences Inc.
  • Grifols, S.A.
  • Octapharma AG
  • Green Cross Corporation
  • Baxter International Inc.
  • CSL Behring LLC
  • Renaissance Acquisition Holdings LLC

Report Scope:

The report segments the global plasminogen market as follows:

By Type:

  • Intravenous Injection
  • Eye Drops

By Application:

  • Ligneous Conjunctivitis
  • Diabetic Foot
  • Wound Healing
  • Others

By Region:

  • North America (United States, Canada, Mexico)
  • Europe (France, United Kingdom, Italy, Germany, Spain)
  • Asia-Pacific (China, India, Japan, Australia, South Korea)
  • South America (Brazil, Argentina, Colombia)
  • Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report provides a detailed analysis of key players in the global plasminogen market. Customizations are available to tailor the report to specific company needs, including additional profiling of up to five market players.

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Plasminogen Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Intravenous Injection, Eye Drops)
    • 4.2.2. By Application (Ligneous Conjunctivitis, Diabetic Foot, Wound Healing, Others)
    • 4.2.3. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By Application
    • 4.3.3. By Region

5. Asia Pacific Plasminogen Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Application
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Plasminogen Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Application
    • 5.3.2. India Plasminogen Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Application
    • 5.3.3. Australia Plasminogen Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Application
    • 5.3.4. Japan Plasminogen Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Application
    • 5.3.5. South Korea Plasminogen Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Application

6. Europe Plasminogen Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Plasminogen Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Germany Plasminogen Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Spain Plasminogen Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
    • 6.3.4. Italy Plasminogen Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Application
    • 6.3.5. United Kingdom Plasminogen Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Application

7. North America Plasminogen Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Plasminogen Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. Mexico Plasminogen Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Canada Plasminogen Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application

8. South America Plasminogen Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Plasminogen Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Argentina Plasminogen Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Colombia Plasminogen Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application

9. Middle East and Africa Plasminogen Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Plasminogen Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Saudi Arabia Plasminogen Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. UAE Plasminogen Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Plasminogen Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Boehringer Ingelheim Inc. GmbH
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Kedrion S.p.A
  • 14.3. Genentech
  • 14.4. Prometic Life Sciences Inc
  • 14.5. Grifols, S.A
  • 14.6. Octapharma AG
  • 14.7. Green Cross Corporation
  • 14.8. Baxter International Inc.
  • 14.9. CSL Behring LLC
  • 14.10.Renaissance Acquisition Holdings LLC

15. Strategic Recommendations

16. About Us & Disclaimer